evenamide (NW-3509) / Newron  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
evenamide (NW-3509) / Newron
NCT02624167: A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia

Completed
2a
90
US, RoW
NW-3509A, Placebo
Newron Pharmaceuticals SPA
Chronic Schizophrenia
12/16
01/17
NCT04461119: Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

Checkmark Safety and tolerability data in schizophrenia
Apr 2021 - Apr 2021: Safety and tolerability data in schizophrenia
Completed
2
138
US, RoW
Evenamide, NW-3509, Placebo
Newron Pharmaceuticals SPA
Schizophrenia
02/21
03/21
2020-000437-41: A pilot, open-label, rater-blinded, randomized, parallel-group, multi-center study to evaluate the safety, tolerability and preliminary efficacy of three add-on fixed doses of Evenamide in patients with treatment-resistant schizophrenia (TRS). Studio multicentrico pilota, in aperto, randomizzato, per valutare sicurezza, tollerabilità ed efficacia preliminare in tre gruppi paralleli con tre dosi fisse di Evenamide somministrate come terapia aggiuntiva a pazienti affetti da schizofrenia resistente al trattamento (TRS).

Not yet recruiting
2
150
Europe
Evenamide, [NW-3509], Capsule, hard
NEWRON PHARMACEUTICALS SPA
Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
2020-000439-32: An open-label, multi-center, extension study to evaluate the long-term safety, tolerability and preliminary efficacy of Evenamide as add-on treatment in patients with treatment-resistant schizophrenia (TRS) not responding adequately to their current antipsychotic medication. Studio di estensione in aperto, multicentrico per valutare sicurezza, tollerabilità ed efficacia preliminare a lungo termine di evenamide come terapia aggiuntiva in pazienti affetti da schizofrenia resistente al trattamento (TRS) che non rispondono adeguatamente al farmaco antipsicotico attualmente in corso

Not yet recruiting
2
150
Europe
Evenamide, [NW-3509], [NE-3509], Capsule, hard
NEWRON PHARMACEUTICALS SPA
Schizophrenia not responding adequately to current antipsychotic treatment Schizofrenia resistente al trattamento con una dose terapeutica stabile di un farmaco antipsicotico, Treatment-resistant schizophrenia (TRS) Schizofrenia trattamento-resistente (TRS), Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 

Download Options